The Aspirin Alternative Your Doctor Never Told You About

New Post Public Reply Private Reply Replies (0) Message Board
wowhappens28
103
The Aspirin Alternative Your Doctor Never Told You About

Pycnogenol--I never heard of it

http://www.greenmedinfo.com/blog/aspirin-alte...-you-about

Aspirin is taken faithfully by millions every day as a preventive measure against heart attack, often without the user having any awareness of the serious health risks associated with it, some potentially fatal. You can view over 60 adverse effects of aspirin on the GreenMedInfo.com's aspirin research page if you have any doubts about how serious a concern this is.

Aspirin's widespread popularity is based on its much-touted blood-thinning properties. But there are safer, surprisingly more effective and far more natural alternatives on the market today.

For instance, pycnogenol, a branded form of an extract of French maritime pine bark, can be found on the shelves of thousands of health food stores around the country, and unique among natural products, has a broad base of human clinical research supporting its use for a wide variety of health conditions. You can view GreenMedInfo.com's pycnogenol research page take a look at the published research.

Moreover, in cross comparison tests, pycnogenol has been found at least as effective as aspirin in preventing blood from clotting, but at significantly lower doses and with a superior safety profile.

Smoker's Study Proves Pycnogenol More Effective and Safer Than Aspirin
In a previous article titled, "The Powerful Aspirin Alternative That Grows on Trees," we featured a 1999 clinical study published in Thrombotic Research that found that when habitual smokers were given either 500 mg of aspirin or anywhere between 100-200 mg of pycnogenol, the pycnogenol group experienced equivalent platelet aggregation inhibiting effects but with much lower bleeding times:

"Thus, smoking-induced enhanced platelet aggregation was inhibited by 500 mg Aspirin as well as by a lower range of 100-125 mg Pycnogenol. Aspirin significantly (p<0.001) increased bleeding time from 167 to 236 seconds while Pycnogenol did not.These observations suggest an advantageous risk-benefit ratio for Pycnogenol."

This is a highly significant finding, as aspirin-induced bleeding can result in significantly increased morbidity and mortality. One might ask, if pycnogenol is as effective a 'blood thinner' as aspirin but without the same side effects, then what is the downside of using the natural alternative?



New Study Confirms Pycnogenol's Superiority to Aspirin
Research comparing pycnogenol to aspirin as a blood thinner has been sparse, but a new study promises to add additional weight to the previously reported finding of pycnogenol's superiority. Published this year in the Italian journal Panminerva Medica and titled, "Recurrence of retinal vein thrombosis with Pycnogenol® or Aspirin® supplementation: a registry study," researchers compared the use of either pycnogenol or aspirin in the prevention of retinal vein thrombosis recurrence after a first episode.

Retinal vein thrombosis is considered to be a relatively common condition intimately related to other conditions that afflict the vascular system, such as hypertension, arteriosclerosis and diabetes.[1]

The study methods were described as follows:

Possible management options - chosen by patients - were: standard management; standard management + oral Aspirin® 100 mg once/day (if there were no tolerability problems before admission); standard management + Pycnogenol® two 50 mg capsules per day (for a total of 100 mg/day). Number of subjects, age, sex, distribution, percentage of smokers, and vision were comparable."

The results were reported as follows:

Recurrent RVT was seen in 17.39% of controls and in 3.56% of subjects supplemented with Pycnogenol® (P<0.05 vs. controls). There was RVT in 15.38% of the subjects using Aspirin®. The incidence of RVT was 4.88 times higher with standard management in comparison with the supplement group and 4.32 lower with Pycnogenol® supplementation in comparison with Aspirin®. Vision level was better with Pycnogenol® (20/25 at nine months; P<0.05). With Pycnogenol®, edema at the retinal level was also significantly reduced compared to the other groups. Pycnogenol® has a very good safety profile. In the Aspirin® group 26 completed 9 months and 6 subjects dropped out for tolerability problems. In the Aspirin® group, 2 minor, subclinical, retinal, hemorrhagic episodes during the follow-up were observed (2 subjects out of 26, equivalent to 7.69%). This pilot registry indicates that Pycnogenol® seems to reduce the recurrence of RVT without side effects. It does not induce new hemorrhagic episodes that may be theoretically linked to the use of Aspirin® (or other antiplatelets)."

As you can see, the clear winner in this comparison study was pycnogenol. Not only was the incidence of recurrent retinal vein thrombosis almost five times higher in the aspirin group, vision and retinal swelling (edema) was significantly lower in the pycnogenol group, as well. Moreover, whereas the pycnogenol group had no reported side effects, 6 of the 26 subjects in the aspirin group dropped out due to tolerability issues, and 7.69% of the aspirin group (2 subjects of 26) were found to have retinal bleeding as a side effect in the follow-up period.

Nature Provides Time-Tested Solutions
We really shouldn't be surprised that a naturally occurring complex of phytocompounds (i.e. pycnogenol) should outperform a synthetic drug, considering that our bodies have co-evolved for millions of years with natural things, (e.g. foods, herbs, spices), and only a hundred or more with synthetic ones, (e.g. patent drugs). Pycnogenol, as a bark extract, is about 65-75 percent proanthocyanidins (procyanidins), a class of polyphenols found in a wide variety of plants, many of which have been in the human diet since the inception of our species and before. Some classical examples include green and black tea, cranberry, bilberry, cocoa beans, cinnamon, and black currant. Polyphenols, of course, are powerful antoxidants, as well as signaling molecules, which likely perform a variety of gene-regulatory functions, that may have value in a wide range of health conditions. Indeed, we have indexed over 150 health benefits linked to polyphenol consumption on our database alone.

Suffice it to say that as the biomedical machine moves forward, and we see an increasingly voluminous body of literature investigating the health benefits and mechanisms of action underpinning natural interventions for disease prevention and treatment, we will become increasingly compelled to choose time-tested, natural alternatives to synthetic chemicals, as the former are not only much safer but often more effective than most scientists and physicians ever dreamed possible.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

7-Eleven Rolls Out Korean Flavors in Bold Menu Shift

Updated Category News Views 175

7-Eleven's New Global Menu Twist October 2026 sees 7-Eleven, Inc. whip out an intriguing move, venturing east with its new Flavors of Korea menu. They're not just changing the game in convenience store aisles; they're dancing to the beat of global flavors—a shake-up fit for the world's largest convenience retailer. Think about bodega basics getting a spicy Korean...

Continue Reading
Air Force Enlisted Village: Trailblazing Senior Care

Updated Category News Views 31

Changing the Senior Living Game for Military Families Out of all the fancy talk shows and slick productions, "All Access hosted by Andy Garcia" managed to hit a real nerve on the quiet, critical shifts happening in the senior living sector. They dug into how Air Force Enlisted Village in Shalimar is taking care of our military families' unsung heroes—the surviving...

Continue Reading
JELD-WEN Kicks Off 2027 Senior Notes Exchange

Updated Category News Views 164

A Fresh Play: Swapping Old for New With a fresh brew in hand and the latest company maneuvers on the table, JELD-WEN's move to exchange its 4.875% Senior Notes due 2027 for new secured notes maturing in 2031 comes into focus. This ain't just some routine shuffling of papers. They're calling up eligible folks holding onto those old notes, saying, 'Why stick with the old...

Continue Reading
Max Stock Gears Up for Q3 Earnings Report Nov. 17

Updated Category News Views 83

Max Stock's Q3 Earnings Anticipation Ah, it’s that time again—when we wait with bated breath for another round of quarterly earnings. Max Stock Ltd. (TASE: MAXO) is prepping to spill the beans on their third quarter 2026 performance, with a conference call scheduled for November 17. Big day? You bet. Who's Leading the Call? The brains behind the operation, CFO Paz Oz...

Continue Reading
Aker BP's Q3 2026: Strong Earnings Fuel Optimism

Updated Category News Views 126

Third Quarter Overview: Riding the Wave Aker BP's third quarter report is a raucous symphony of successes that have the market nodding in admiration. Marking significant strides with their offshore projects, the company seems to be in a cavalier mood as it boasts higher sales volumes and promising financials. Net production came in at 374 mboepd, dampened slightly by...

Continue Reading
Pencil Reinvention Aims to Reduce Classroom Waste

Updated Category News Views 20

Sharpen Those Ideas: Reinventing the Humble Pencil Every classroom has 'em: pencils chewed up faster than a kid chomping through bubblegum. This ain't new. But dig this—a Chicago teacher's coming in hot with a tweak to extend pencil life. How? By addressing the ol' crumbly eraser issue. You know, the kind that vanishes into thin air right when you need it most. So,...

Continue Reading
Life Time's Q3 2026 Results Highlight Solid Growth

Updated Category News Views 49

Life Time Rolls On With Strong Q3 Performance Sometimes the market hands you pure gold, and that's what Life Time (NYSE: LTH) has right now. They didn't just have a decent quarter; they outright nailed it with a $893.5 million total revenue haul—a hefty 14.2% rise from the prior year. What's driving this ship? Solid growth in membership dues and dynamic personal...

Continue Reading
Bitcoin Mortgages: APX Ushers in New Canadian Era

Updated Category News Views 23

Bitcoin Meets Canadian Mortgages: A Game Changer? Here's a scenario you didn't see coming: Bitcoin, the digital darling of the new millennium, now backing Canadian mortgages. If that doesn't get your financial senses tingling, maybe you haven't been paying attention. APX Lending, a pioneer in digital-asset-backed lending, is kicking open the doors to a fresh financial...

Continue Reading
Cohere's CAD $7 Billion Raise Signals AI Power Shift

Updated Category News Views 64

Changing the Game: Cohere's Massive Series E Raise There's a seismic shift happening up north, and it’s not the aurora borealis. Cohere just announced the initial close of a staggering CAD $7 billion Series E funding round, eyeing a CAD $35.7 billion valuation. If it pans out, it’d be the kind of cash grab that's never been seen in Canadian tech history. Why This...

Continue Reading
CallRail's New Insight Tool: Navigating the Competitive Landscape

Updated Category News Views 28

How CallRail's New Feature Changes the Game Ever sit in a boardroom meeting and wonder what your lead numbers really mean? CallRail just dropped a new feature that could change that. This AI-powered platform is now decking its 225,000 businesses with market insights to not just know their numbers but to understand how they stack up against their competition in the same...

Continue Reading

Top 5 Most Recently Viewed Articles

Analyzing Apple's Position in the Competitive Tech Landscape

Updated Category News Views 226

Understanding Apple's Market Dynamics in Tech In today's fast-paced business environment, assessing company performances is crucial for investors and tech enthusiasts. This article delves into a detailed examination of Apple Inc. (NASDAQ: AAPL) within the Technology Hardware, Storage & Peripherals sector, evaluating its financial health, market competitiveness, and growth...

Continue Reading
ECGI Holdings Expands into FinTech with RezyFi Acquisition Deal

Updated Category News Views 158

ECGI Holdings Marks Its Entry into FinTech with a $30 Million LOI Acquisition signals a bold step for ECGI into the financial technology sector, establishing a foundation for future innovations focused on AI and blockchain in mortgage operations. Details of the Acquisition Agreement Today, ECGI Holdings, Inc. (OTC: ECGI) revealed that it has signed a binding Letter of...

Continue Reading
Discover DAISE: A Fresh Fragrance Revolution for Young Generations

Updated Category News Views 418

Introducing DAISE: A Unique Fragrance Experience DAISE is an innovative line of mood-matching fragrance and body care products crafted to resonate with the lively spirit of younger consumers. This fresh brand, birthed from the creativity of the co-founder of MONDAY Haircare, has officially launched its offerings, both in-store and online at Target. The focus of DAISE is...

Continue Reading
Transforming Media Planning: The Liftlab and Stellair Alliance

Updated Category News Views 187

Transforming Media Planning: The Liftlab and Stellair Alliance In a rapidly evolving media landscape, Liftlab is partnering with Stellair to reshape how brands approach media planning and execution. This collaboration aims to address significant challenges associated with effectively utilizing data for marketing initiatives. As companies navigate the complexities of...

Continue Reading
Northland Power's Q1 2025 Achievements and Future Growth Plans

Updated Category News Views 658

Overview of Northland Power's Q1 2025 Results In an exciting update from Northland Power Inc. (TSX: NPI), the company announced that it achieved significant milestones in the first quarter of 2025. With ongoing efforts in expanding renewable energy sources, Northland's performance showcases its commitment to a sustainable future. Oneida's energy storage project commenced...

Continue Reading